Vertex Pharmaceuticals · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← VRTX

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q2	2026-06-30	3.33	+12.5%	85.3%	1.25	1.10	33.0%	1.01	4.31	0.47	—
FY2026 Q1	2026-03-31	2.99	+7.8%	86.8%	1.14	1.03	34.5%	1.29	4.02	0.34	—
FY2025 Q4	2025-12-31	3.19	+9.5%	85.4%	1.21	1.19	37.3%	0.35	4.64	0.13	—
FY2025 Q3	2025-09-30	3.08	+11.0%	86.5%	1.19	1.08	35.2%	1.14	4.20	1.07	—
FY2025 Q2	2025-06-30	2.96	+12.1%	86.3%	1.15	1.03	34.8%	0.93	3.99	0.39	—
FY2025 Q1	2025-03-31	2.77	+3.0%	86.9%	0.63	0.65	23.3%	0.78	2.49	0.43	—
FY2024 Q4	2024-12-31	2.91	+15.7%	85.5%	1.03	0.91	31.4%	0.49	3.62	0.42	—
FY2024 Q3	2024-09-30	2.77	+11.6%	85.8%	1.12	1.05	37.7%	1.30	4.01	0.31	—
FY2024 Q2	2024-06-30	2.65	+6.1%	85.9%	-3.51	-3.59	-135.8%	-3.82	-13.92	0.32	—
FY2024 Q1	2024-03-31	2.69	+13.3%	87.3%	1.14	1.10	40.9%	1.24	4.21	0.13	—
FY2023 Q4	2023-12-31	2.52	+9.3%	85.4%	0.99	0.97	38.5%	0.18	3.71	0.15	—
FY2023 Q3	2023-09-30	2.48	+6.4%	87.2%	1.04	1.04	41.7%	1.23	3.97	0.12	—
FY2023 Q2	2023-06-30	2.49	—	87.6%	1.03	0.92	36.7%	1.07	3.52	0.03	—
FY2023 Q1	2023-03-31	2.37	—	88.8%	0.78	0.70	29.5%	0.86	2.69	0.13	—
FY2022 Q4	2022-12-31	2.30	—	87.7%	1.03	0.82	35.6%	1.04	3.14	0.00	—
FY2022 Q3	2022-09-30	2.33	—	87.6%	1.13	0.93	39.9%	0.90	3.59	0.00	—

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.